KINAXO enters into agreement with Schering AG on kinase inhibitor profiling
"We are delighted to enter into this collaboration with Schering AG. It underlines the benefits of our technology platform for developing the next generation of kinase inhibitors," said Dr. Andreas Jenne, CEO of KINAXO. "The KinaTorTM technology permits rational decisions based on proteome-wide selectivity data and greatly facilitates the development of clean and spectrum-selective kinase drugs with well-characterized inhibition profiles."
The KinaTor(TM) technology uses immobilized kinase inhibitors to detect their protein binding partners in cell lines or tissue samples. Affinity-based separation procedures in combination with sensitive mass spectrometry and biochemical assays allow KINAXO to identify and quantify the protein-small molecule interactions of kinase inhibitors.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!